- The FDA has accepted for review Coherus BioSciences Inc's (NASDAQ: CHRS) marketing application for CHS-1420 and AbbVie's Inc (NYSE: ABBV) Humira (adalimumab) biosimilar product candidate, with action for December 2021.
- If approved, Coherus plans to launch the adalimumab biosimilar in the U.S. on or after July 1, 2023.
- The company says that annual U.S. Humira sales are projected to exceed $18 billion by the planned launch.
- Humira is indicated for a range of diseases.
- Price Action: CHRS shares are down 0.34% at $17.38 on last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
